These processes include the breakdown and/or dysfunction of the blood–brain barrier (BBB); carriers of the gene variant APOE4 and its link to BBB; and neuroinflammation, in addition to type 2 diabetes (T2DM), metabolic syndrome (MS), and brain insulin resistance (IR). The gene discussed is APOE; the disease is myeloid sarcoma.